News coverage about Cytori Therapeutics (NASDAQ:CYTX) has trended somewhat positive on Wednesday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cytori Therapeutics earned a news impact score of 0.19 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.6120718524604 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Cytori Therapeutics (CYTX) & Inogen (INGN) Critical Comparison (americanbankingnews.com)
- Cytori Therapeutics, Inc. (CYTX) Forms $0.33 Double Bottom; The … – Hill Country Times (hillcountrytimes.com)
- Today’s Hot Stock Under Review – Cytori Therapeutics, Inc. (NASDAQ: CYTX) – The Investor Guide (wallstreetnews24.com)
- Cytori Therapeutics Inc’s (CYTX) Earnings Declined 36.4%, But How Did It Fare Against The Industry? (finance.yahoo.com)
- Cytori Closes Rights Offering for Gross Proceeds of $10 Million – GlobeNewswire (press release) (globenewswire.com)
Shares of Cytori Therapeutics (NASDAQ:CYTX) opened at $0.28 on Wednesday. Cytori Therapeutics has a twelve month low of $0.27 and a twelve month high of $2.13.
Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.02. The company had revenue of $1.77 million during the quarter, compared to the consensus estimate of $2.04 million. Cytori Therapeutics had a negative net margin of 367.33% and a negative return on equity of 228.21%. During the same quarter in the prior year, the firm posted ($0.26) EPS. equities analysts predict that Cytori Therapeutics will post -0.62 earnings per share for the current year.
A number of analysts have recently weighed in on CYTX shares. Maxim Group set a $5.00 price target on shares of Cytori Therapeutics and gave the stock a “buy” rating in a report on Friday, August 11th. B. Riley reaffirmed a “neutral” rating on shares of Cytori Therapeutics in a report on Friday, August 11th. Finally, Zacks Investment Research downgraded shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 9th.
COPYRIGHT VIOLATION WARNING: This article was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://ledgergazette.com/2017/12/06/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-cytori-therapeutics-cytx-share-price.html.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.